IP Library › Granted Patent US 8,778,275
Granted Patent B2
US 8,778,275 · App. 12/928,165 · Granted Jul 15, 2014

Methods for producing vaccine adjuvants

Inventors: Harald Rueckl (Alsfeld, DE); Hanno Scheffczik (Marburg, DE)
Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,778,275
App. No.
12/928,165
Granted
Jul 15, 2014
Kind
B2
Abstract

An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane.

Claims (18)

1. A method for the manufacture of an oil-in-water emulsion comprising:

passing a first emulsion having a first average oil droplet size through a microfluidization device to form a second emulsion having a second average oil droplet size which is less than the first average oil droplet size;

wherein the microfluidization device comprises an interaction chamber which comprises a plurality of Z-type channels and a back pressure chamber comprising at least one channel; and

wherein the back pressure chamber is positioned downstream of the interaction chamber.

2. The method of claim 1 , wherein the first emulsion is introduced into the interaction chamber at a first pressure and the second emulsion exits the back pressure chamber at a second pressure which is lower than the first pressure; and wherein between 80 and 95% of the pressure difference between the first and the second pressures is dropped across the interaction chamber and 5 to 20% of the pressure difference between the first and the second pressures is dropped across the back pressure chamber.

3. The method of claim 1 , wherein the back pressure chamber comprises a plurality of channels.

4. The method of claim 1 , comprising filtration of the second emulsion.

5. The method of claim 1 , comprising the step of formation of the first emulsion using a homogenizer.

6. The method of claim 1 , wherein the first average oil droplet size is 5000 nm or less.

7. The method according to claim 1 , wherein the number of oil droplets having a size of >1.2 μm in the first emulsion is 5×10 11 /ml or less.

8. The method of claim 1 , wherein the second average oil droplet size is 500 nm or less.

9. The method according to claim 1 , wherein the number of oil droplets having a size of >1.2 μm in the second emulsion is 5×10 10 /ml or less.

10. A method for preparing a vaccine composition, comprising preparing an emulsion according to claim 1 and combining the emulsion with an antigen.

11. A method for preparing a vaccine kit comprising preparing an emulsion according to claim 1 and packaging the emulsion into a kit as a kit component together with an antigen component.

12. The method of claim 11 , wherein the kit components are in separate vials; for example, wherein the vials are made from borosilicate glass.

13. The method of claim 10 , wherein the emulsion is a bulk adjuvant and the method comprises extracting unit doses from the bulk adjuvant for packaging as kit components.

14. The method of claim 10 , wherein the antigen is an influenza virus antigen; for example, wherein the combination of the emulsion and the antigen forms a vaccine composition and wherein the vaccine composition includes about 15 μg, about 10 μg, about 7.5 μg, about 5 μg, about 3.8 μg, about 1.9 μg, about 1.5 μg of hemagglutinin per influenza virus strain.

15. The method of claim 1 , wherein: the interaction chamber has a plurality of fixed geometry channels into which the emulsion passes and in which the emulsion is accelerated under pressure to reduce the emulsion's oil droplet size and reduce the number of oil droplets having a size >1.2 μm; wherein channels in the interaction chamber include a plurality of substantially right-angled corners; and wherein the back pressure chamber has at least one fixed geometry channel into which the emulsion passes.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: NOVARTIS AG
To: SEQIRUS UK LIMITED
Reel/Frame 069642/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2012
From: RUECKL, HARALD; SCHEFFCZIK, HANNO; SANTRY, BARBARA
To: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
Reel/Frame 029367/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2012
From: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
To: NOVARTIS AG
Reel/Frame 029367/0758 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2011
From: RUECKL, HARALD; SCHEFFCZIK, HANNO
To: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
Reel/Frame 025976/0035 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2011
From: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
To: NOVARTIS AG
Reel/Frame 025976/0616 →
Priority Claims (1)
DE 10 2009 056 884 · Dec 3, 2009 · national
Continuity (2)
Provisional Application 61283548 · Dec 3, 2009
Related Publication 20110165193A1 · Jul 7, 2011